Eagle Pharmaceuticals (EGRX) Competitors $3.00 +0.11 (+3.63%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Fate Therapeutics (NASDAQ:FATE) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts recommend FATE or EGRX? Fate Therapeutics currently has a consensus price target of $3.83, suggesting a potential upside of 234.79%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Fate Therapeutics is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is FATE or EGRX more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Eagle Pharmaceuticals' return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% Eagle Pharmaceuticals N/A N/A N/A Which has more risk & volatility, FATE or EGRX? Fate Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Do institutionals & insiders hold more shares of FATE or EGRX? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, FATE or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.63-$186.26M-$1.49-0.77Eagle Pharmaceuticals$257.55M0.15$35.64MN/AN/A Does the media refer more to FATE or EGRX? In the previous week, Fate Therapeutics had 4 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for Fate Therapeutics and 0 mentions for Eagle Pharmaceuticals. Fate Therapeutics' average media sentiment score of 0.03 beat Eagle Pharmaceuticals' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fate Therapeutics Neutral Eagle Pharmaceuticals Neutral SummaryFate Therapeutics beats Eagle Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.96M$813.46M$5.54B$8.95BDividend YieldN/A4.84%5.38%4.08%P/E RatioN/A1.1027.4020.04Price / Sales0.15220.40419.46118.60Price / Cash0.4023.4436.6357.47Price / BookN/A6.108.085.67Net Income$35.64M-$27.81M$3.16B$248.47M7 Day Performance11.11%0.67%2.12%2.90%1 Month Performance51.90%7.16%4.43%5.75%1 Year Performance-45.45%7.88%35.62%21.36% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals2.3159 of 5 stars$3.00+3.6%N/A-44.6%$38.96M$257.55M0.00100Gap DownFATEFate Therapeutics4.0575 of 5 stars$1.14-4.2%$3.83+236.3%-65.2%$136.38M$13.63M-0.77550News CoverageGap UpKYTXKyverna Therapeutics1.743 of 5 stars$3.22+4.9%$18.50+474.5%-64.8%$132.68M$7.03M-0.9596News CoverageBDTXBlack Diamond Therapeutics3.2879 of 5 stars$2.27-2.6%$14.60+543.2%-38.2%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.2846 of 5 stars$0.56-3.4%$3.00+435.3%-35.4%$132.42M$28.70M-2.08120LXEOLexeo Therapeutics1.752 of 5 stars$3.96+1.3%$16.60+319.2%-68.8%$129.80M$650K-1.2058News CoverageLYELLyell Immunopharma2.7754 of 5 stars$8.99+3.5%$20.00+122.5%-68.8%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-3.0%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.6169 of 5 stars$0.75-5.1%$9.29+1,144.7%-92.0%$127.08MN/A-0.46108News CoveragePositive NewsGap UpNKTXNkarta2.2595 of 5 stars$1.75-1.4%$14.33+721.4%-66.9%$125.60MN/A-1.16140News CoverageFTLFFitLife Brands4.0633 of 5 stars$12.99-2.5%$20.50+57.8%-19.0%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies FATE Alternatives KYTX Alternatives BDTX Alternatives VXRT Alternatives LXEO Alternatives LYEL Alternatives BYSI Alternatives NMRA Alternatives NKTX Alternatives FTLF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts